Avian influenza medical therapy

Jump to navigation Jump to search

Avian influenza Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Avian influenza from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Avian influenza medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Avian influenza medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Avian influenza medical therapy

CDC on Avian influenza medical therapy

Avian influenza medical therapy in the news

Blogs on Avian influenza medical therapy

Directions to Hospitals Treating Avian influenza

Risk calculators and risk factors for Avian influenza medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Studies done in laboratories suggest that some of the prescription medicines approved in the United States for human influenza viruses should work in treating avian influenza infection in humans. However, influenza viruses can become resistant to these drugs, so these medications may not always work. The H5N1 virus that has caused human illness and death in Asia is resistant to amantadine and rimantadine, two antiviral medications commonly used for influenza. Two other antiviral medications, oseltamivir and zanamivir, would probably work to treat influenza caused by H5N1 virus, but additional studies still need to be done to demonstrate their effectiveness.

Medical Therapy

  • Preliminary evidence demonstrates that neuraminidase inhibitors can reduce the duration of viral replication and improve survival among patients with avian influenza. In cases of suspected avian influenza, one of the following 3 neuraminidase inhibitors should be administered as soon possible, preferably within 48 hours of symptom onset.
Antiviral Agents for the Treatment of Avian Influenza
Agent Recommended Dose Duration
Oseltamivir 75 mg PO once daily
(Patients with severe disease may have diarrhea and may not absorb oseltamivir efficiently)
A minimum of 10 days
Zanamivir 10 mg inhaled twice daily for 5 days
(Preferred if patients has diarrhea and malabsorption)
A minimum 5 days
Peramivir 600 mg IV as a single dose
(Preferred if patients has diarrhea and malabsorption)
1 day
  • The use of corticosteroids is not recommended.
  • Physicians may consider increasing either the recommended daily dose and/or the duration of treatment in cases of severe disease.
  • The use of adamantine is not recommended as most H5N1 and H7N9 avian influenza viruses are resistant to it.

References

Template:WH Template:WS